Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: CCND1 Positive, CCND2 Positive, CCND3 Positive, CD20 Positive, Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Ibrutinib, Laboratory Biomarker Analysis, Rituximab; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay; Drug · Other
Lead sponsor: Razor Genomics; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 18
States / cities: Mission Viejo, California • Sacramento, California • Santa Rosa, California + 15 more

Conditions: Prostate Cancer
Interventions: 177Lu-PSMA-617, Stereotactic Body Radiotherapy (SBRT); Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer
Interventions: PCR/PCR/LDR Strategy; Genetic
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 21,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Mental Health
Interventions: Implementation Facilitation, Centralized Technical Assistance; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 81,424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 17
States / cities: Prescott, Arizona • Tucson, Arizona • Palo Alto, California + 14 more

Conditions: Breast Cancer
Interventions: pegfilgrastim, AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 3,294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2027
U.S. locations: 539
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 369 more

Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Selumetinib, Docetaxel, Placebo, Pegylated G-CSF; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 17
States / cities: Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more

Conditions: Psoriasis
Interventions: IDP-122 Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 7
States / cities: Fountain Valley, California • Thousand Oaks, California • Doral, Florida + 3 more

Conditions: Addiction, Alcohol Use Disorder
Interventions: Take Control, Semaglutide; Behavioral · Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mechanical Ventilation
Interventions: Electronic Alerts; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Essential Tremor
Interventions: Exablate Model 4000 Type 1.0/1.1; Device
Lead sponsor: InSightec; Industry
Eligibility: 22 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Stanford, California • Baltimore, Maryland • New York, New York + 4 more

Conditions: Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
Interventions: Selpercatinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Months to 21 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more

Conditions: Opioid Agonist Treatment, Alcohol Use Disorder, Opioid Use Disorder
Interventions: Digital Contingency Management Intervention Arm, Digital Wellness Arm; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 19 Years to 63 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Chronic Kidney Diseases
Interventions: Fruits and Vegetable increase; Other
Lead sponsor: Nand Wadhwa; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Port Jefferson Station, New York

Conditions: Memory
Interventions: Different cognitive and memory demands during the memory experiment, Different electrical stimulation parameters during cognitive and memory demands; Behavioral · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 70 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Preeclampsia, Hypertension in Pregnancy
Interventions: Labetalol, Nifedipine; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Avascular Necrosis, Osteonecrosis
Interventions: Genex with ABMC; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cognitive Function
Interventions: Clarity Product Placebo Control, RS Clarity Active Product; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 35 Years to 60 Years
Enrollment: 990 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Group B Streptococcal Infections
Interventions: IVT GBS-06, Placebo; Biological
Lead sponsor: Inventprise Inc.; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Hepatocellular Carcinoma
Interventions: Durvalumab, Tremelimumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: La Jolla, California • Shreveport, Louisiana • Detroit, Michigan

Conditions: Weber B Ankle Fractures
Interventions: Gravity assisted stress, Manual external rotation stress, Weight-bearing stress; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Highly Sensitized Prospective Kidney Transplant Recipients
Interventions: carfilzomib, belatacept, Bone marrow aspiration; Biological · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13,378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

Behavioral Health Interdisciplinary Program - Collaborative Chronic Care Model (BHIP-CCM) Enhancement Project 2.0

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

Semaglutide Therapy for Alcohol Reduction (STAR)

Titration of Oxygen Levels During Mechanical Ventilation With Electronic Alerts

Bilateral Treatment of Medication Refractory Essential Tremor

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Mobile Platform for Optimizing Wellness and Engagement in Recovery

Evaluation of Increased Fruits and Vegetables Consumption in Chronic Kidney Disease

Basic Experimental Study of Hippocampal Memory Functions

Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery

Preeclampsia Postpartum Antihypertensive Treatment

The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head

Radicle Clarity DSTTM: A Study Assessing the Impact of Health and Wellness Products on Mental Clarity and Related Health Outcomes

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

Analysis of Medial Clear Space Widening in Weber B Ankle Fractures

Carfilzomib and Belatacept for Desensitization

Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic